Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2024-02-07 Annual Report
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'Lundbeck Annual Report 2023' and contains detailed sections typical of an annual report, including a management review, business model description, financial key figures for multiple years, key events, governance, sustainability metrics, and scientific developments. It includes comprehensive financial data such as revenue, EBITDA, net profit, and cash positions, as well as strategic and operational information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-02-07 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document explicitly states "Lundbeck Annual Report 2023" and mentions it is submitted in XHTML format to the Danish Financial Supervisory Authority. This strongly indicates the content is the Annual Report itself. Although the document is short and contains links (suggesting an announcement wrapper), the primary subject matter and title directly correspond to the definition of an Annual Report (10-K). Given the explicit title 'Annual Report 2023', the classification should prioritize the content type over the wrapper format, especially since the wrapper is announcing the submission of the official report. However, applying the 'MENU VS MEAL' rule: the text is very short (997 chars) and primarily serves to announce the availability of the report (providing links to PDF/ZIP). Therefore, it is classified as a Report Publication Announcement (RPA) announcing the release of the Annual Report, rather than the full 10-K document itself.
2024-02-07 English
Lundbeck Annual Report 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'Lundbeck Annual Report 2023' and contains comprehensive sections including Management Review, Financial Statements, Governance, and Sustainability data. It is a full-length annual report covering the company's yearly performance, strategy, and financial results, fitting the definition of a 10-K (Annual Report). FY 2023
2024-02-07 English
Earnings Release 2023
Earnings Release Classification · 100% confidence The document presents key financial highlights for the full year 2023 (FY 2023) and the fourth quarter (Q4 2023), including revenue, adjusted EBITDA, and EPS figures, along with forward-looking guidance for 2024. This structure—summarizing period results and providing management commentary—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on the 'Key highlights' and 'Key figures' summary rather than the full statutory financial statements. The presence of a CEO quote and financial guidance strongly supports the ER classification. FY 2023
2024-02-07 English
Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024
Earnings Release Classification · 95% confidence The document is a 'Corporate Release' from Lundbeck detailing financial results for the full year 2023. It includes key highlights, revenue breakdowns, business performance, and financial guidance. While it contains comprehensive financial data, it explicitly states on page 3 that 'This Corporate release should not be seen as a financial report in accordance with IAS 34' and directs readers to the separate 'Annual Report' for full financial statements. Because this is an initial announcement of financial results (key highlights) rather than the full audited Annual Report (10-K) or an interim report (IR), it is classified as an Earnings Release. FY 2023
2024-02-07 English
Earnings Release 2024
Earnings Release Classification · 95% confidence The document is a press release from H. Lundbeck A/S announcing the results of a Phase II clinical trial (AMULET) for a drug candidate (Lu AF82422) in treating Multiple System Atrophy (MSA). It details clinical outcomes, mentions that full results are forthcoming, and includes a section for a conference call/webcast. This type of announcement, focusing on clinical trial results and immediate market/investor communication, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about R&D progress, it is more specific than a generic RNS. However, it is not a comprehensive financial report (10-K or IR), nor is it a transcript (CT) or a formal presentation (IP). It is an initial announcement of results, which aligns best with the 'Earnings Release' (ER) category, as clinical trial updates often serve as the primary 'earnings' driver for biotech/pharma companies, even if not strictly quarterly financial earnings. Given the context of immediate market disclosure, ER is the most appropriate fit among the specific options, although RNS is a close secondary possibility if ER is strictly reserved for revenue/profit announcements. Since it announces key performance indicators (trial results) and includes forward-looking statements, ER is selected. Q1 2024
2024-01-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.